These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10341859)

  • 1. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin.
    Rahim A; O'Neill PA; Shalet SM
    Clin Endocrinol (Oxf); 1999 Jan; 50(1):77-84. PubMed ID: 10341859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.
    Korbonits M; Kaltsas G; Perry LA; Putignano P; Grossman AB; Besser GM; Trainer PJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2489-95. PubMed ID: 10404825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
    Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations.
    Arvat E; Ramunni J; Bellone J; Di Vito L; Baffoni C; Broglio F; Deghenghi R; Bartolotta E; Ghigo E
    Eur J Endocrinol; 1997 Dec; 137(6):635-42. PubMed ID: 9437229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans.
    Arvat E; Maccagno B; Ramunni J; Di Vito L; Broglio F; Deghenghi R; Camanni F; Ghigo E
    Neuroendocrinology; 1997 Dec; 66(6):432-8. PubMed ID: 9430449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone status during long-term hexarelin therapy.
    Rahim A; O'Neill PA; Shalet SM
    J Clin Endocrinol Metab; 1998 May; 83(5):1644-9. PubMed ID: 9589671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.
    Maccario M; Veldhuis JD; Broglio F; Vito LD; Arvat E; Deghenghi R; Ghigo E
    Eur J Endocrinol; 2002 Mar; 146(3):310-8. PubMed ID: 11888836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans.
    Arvat E; Maccagno B; Ramunni J; Di Vito L; Gianotti L; Broglio F; Benso A; Deghenghi R; Camanni F; Ghigo E
    Neuroendocrinology; 1998 May; 67(5):310-6. PubMed ID: 9641612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hexarelin as a test of pituitary reserve in patients with pituitary disease.
    Korbonits M; Kaltsas G; Perry LA; Grossman AB; Monson JP; Besser GM; Trainer PJ
    Clin Endocrinol (Oxf); 1999 Sep; 51(3):369-75. PubMed ID: 10469018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans.
    Arvat E; Maccagno B; Ramunni J; Giordano R; Broglio F; Gianotti L; Maccario M; Camanni F; Ghigo E
    Eur J Endocrinol; 2000 Nov; 143(5):601-6. PubMed ID: 11078983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study.
    Massoud AF; Hindmarsh PC; Brook CG
    J Clin Endocrinol Metab; 1996 Dec; 81(12):4338-41. PubMed ID: 8954038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients.
    Ciccarelli E; Grottoli S; Razzore P; Gianotti L; Arvat E; Deghenghi R; Camanni G; Ghigo E
    Clin Endocrinol (Oxf); 1996 Jan; 44(1):67-71. PubMed ID: 8706295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of an opiate antagonist on the hormonal changes induced by hexarelin.
    Korbonits M; Trainer PJ; Besser GM
    Clin Endocrinol (Oxf); 1995 Sep; 43(3):365-71. PubMed ID: 7586608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of hexarelin on TRH-induced TSH response in normal adult man.
    Arosio M; Casati G; Biella O; Porretti S; Imbimbo BP; Faglia G
    J Endocrinol Invest; 1998 Apr; 21(4):239-44. PubMed ID: 9624598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of long term erythropoietin therapy on the hypothalamic-pituitary-thyroid axis in patients undergoing capd.
    Tokgöz B; Utaş C; Doğukan A; Oymak O; Keleştimur F
    Ren Fail; 2002 May; 24(3):315-23. PubMed ID: 12166698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
    Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.
    Massoud AF; Hindmarsh PC; Matthews DR; Brook CG
    Clin Endocrinol (Oxf); 1996 May; 44(5):555-62. PubMed ID: 8762732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.